1-15 of 15
Edo Vellenga, PhD.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Jan J Cornelissen, MD PhD, Alois Gratwohl, MD, Kees GM van Montfort, Thomas Pabst, MD, Johan Maertens, MD, H. Berna Beverloo, PhD, Marinus van Marwijk Kooy, P.W. Wijermans, MD, PhD, Bart J Biemond, MD, Dimitri A. Breems, MD, PhD, Edo Vellenga, PhD, Leo F Verdonck, Martin F. Fey, MD, Mojca Lavrencic, MD, PhD, Jeroen JWM Janssen, MD PhD, Gerwin Huls, Jurgen Kuball, MD, PhD, Jakob R. Passweg, MD, Carlos Graux, MD, PhD, Harry C. Schouten, MD, PhD, Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 159.
https://doi.org/10.1182/blood.V118.21.159.159
Published: 2011
Journal Articles

CITED2 Modulates Differentiation and Proliferation of Normal and Leukemic Hematopoietic Stem and Progenitor Cells Downstream of PU.1

Hein Schepers, Ph.D, Patrick M. Korthuis, Jan J. Schuringa, PhD, Gerald de Haan, Ph.D, Edo Vellenga, PhD
Journal: Blood
Blood (2011) 118 (21): 922.
https://doi.org/10.1182/blood.V118.21.922.922
Published: 2011
Journal Articles

Carfilzomib Combined with Thalidomide and Dexamethasone (CARTHADEX) As Induction Treatment Prior to High-Dose Melphalan (HDM) in Newly Diagnosed Patients with Multiple Myeloma (MM). A Trial of the European Myeloma Network EMN

Pieter Sonneveld, MD, PhD, Emilie Hacker, Sonja Zweegman, MD PhD, Marie Jose Kersten, MD, PhD, Edo Vellenga, PhD, Marinus van Marwijk-Kooy, MD, Okke de Weerdt, MD, Sarah Lonergan, MSc, Antonio Palumbo, MD, Henk M. Lokhorst, MD
Journal: Blood
Blood (2011) 118 (21): 633.
https://doi.org/10.1182/blood.V118.21.633.633
Published: 2011
Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Geert A Huls, Lieke H. van der Helm, Canan Alhan, P.W. Wijermans, MD, PhD, Marinus van Marwijk Kooy, Martijn R. Schaafsma, Bart J Biemond, MD, Aart Beeker, Mels Hoogendoorn, Bastiaan P. van Rees, Okke de Weerdt, Jurgen Wegman, Eduard J Libourel, Sylvia A. Luykx-de Bakker, Monique C. Minnema, MD PhD, Rolf Brouwer, Fransien Croon-de Boer, Matthias Eefting, Kon-Siong G. Jie, Arjan A. van der Loosdrecht, Jan Koedam, Nic J.G.M. Veeger, Edo Vellenga, PhD
Journal: Blood
Blood (2011) 118 (21): 3841.
https://doi.org/10.1182/blood.V118.21.3841.3841
Published: 2011
Journal Articles

Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34 + /CD38 low Cells One Year Following Autologous Stem Cell Transplantation

Carolien M Woolthuis, Annet Z Vos, Gerwin Huls, Joost TM de Wolf, Jan J. Schuringa, PhD, Edo Vellenga, PhD
Journal: Blood
Blood (2011) 118 (21): 1893.
https://doi.org/10.1182/blood.V118.21.1893.1893
Published: 2011
Journal Articles

NF-κB and MCL-1 Are Important Determinants for the Effectiveness of Bortezomib In CD34 + AML Versus CD34 − AML Cells

Matthieu C.J. Bosman, Jan J. Schuringa, PhD, Wim J. Quax, PhD, Edo Vellenga, PhD
Journal: Blood
Blood (2011) 118 (21): 1420.
https://doi.org/10.1182/blood.V118.21.1420.1420
Published: 2011
Journal Articles

Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.

Pau Montesinos, MD, Jose D. Gonzalez, PHD, Chelo Rayon, PHD, Javier de la Serna, PHD, Juan Bergua, PHD, Jordi Esteve, PHD, Mar Tormo, PHD, Edo Vellenga, PHD, Elena Amutio, PHD, Guillermo Deben, PHD, Miguel Sanz, PHD
Journal: Blood
Blood (2007) 110 (11): 1838.
https://doi.org/10.1182/blood.V110.11.1838.1838
Published: 2007
Journal Articles

Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.

Miguel A. Sanz, PhD, Pau Montesinos, MD, Edo Vellenga, PhD, Chelo Rayon, PhD, Ricardo Parody, PhD, Javier de la Serna, PhD, Juan Bergua, PhD, Angel Leon, PhD, Silvia Negri, PhD, Concha Rivas, PhD, Salut Brunet, PhD, Marcos Gonzalez, PhD, Jordi Esteve, PhD, Bob Lowenberg, PhD
Journal: Blood
Blood (2007) 110 (11): 590.
https://doi.org/10.1182/blood.V110.11.590.590
Published: 2007
Journal Articles

Central Nervous System Relapse in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Reinforced Anthracycline Monochemotherapy.

Pau Montesinos, MD, Jose D. Gonzalez, PHD, Edo Vellenga, PHD, Chelo Rayon, PHD, Ricardo Parody, PHD, Angel Leon, PHD, Jordi Esteve, PHD, Juan Bergua, PHD, Gustavo Milone, PHD, Miguel A. Sanz, PHD
Journal: Blood
Blood (2007) 110 (11): 592.
https://doi.org/10.1182/blood.V110.11.592.592
Published: 2007
Journal Articles

Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.

Pau Montesinos, MD, Javier de la Serna, PhD, Edo Vellenga, PhD, Consuelo Rayon, PhD, Juan Bergua, PhD, Ricardo Parody, PhD, Jordi Esteve, PhD, Marcos Gonzalez, PhD, Salud Brunet, PhD, Miguel Sanz, PhD
Journal: Blood
Blood (2006) 108 (11): 1503.
https://doi.org/10.1182/blood.V108.11.1503.1503
Published: 2006
Journal Articles

Prognostic Value of Immunophenotype Analysis in Patients with Acute Promyelocytic Leukemia (APL) Treated with All-Transretinoic Acid and Anthracyclin Monochemotherapy.

Pau Montesinos, MD, Concepcion Rivas, PhD, Consuelo Rayon, PhD, Edo Vellenga, PhD, Javier de la Serna, PhD, Juan Bergua, PhD, Ricardo Parody, PhD, Salud Brunet, PhD, Gustavo Milone, PhD, Miguel Sanz, PhD
Journal: Blood
Blood (2006) 108 (11): 2345.
https://doi.org/10.1182/blood.V108.11.2345.2345
Published: 2006
Journal Articles

Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.

Pau Montesinos, MD, Juan Bergua, PhD, Guillermo Martin, PhD, Javier de la Serna, PhD, Edo Vellenga, PhD, Consuelo Rayon, PhD, Ricardo Parody, PhD, Jordi Esteve, PhD, Marcos Gonzalez, PhD, Jose Gonzalez, PhD, Miguel Sanz, PhD
Journal: Blood
Blood (2006) 108 (11): 2010.
https://doi.org/10.1182/blood.V108.11.2010.2010
Published: 2006
Journal Articles

Selective Expression of a Number of ABC Transporter Genes in Normal CD34 + CD38 − Versus CD34 + CD38 − Cells, with a Reverse Pattern in a Subgroup of AML Patients.

Dorina M. van der Kolk, PhD, Susan D.P.W.M. Peeters, Gerald de Haan, PhD, Leonid Bystrykh, PhD, Elisabeth G.E. de Vries, PhD, MD, Edo Vellenga, PhD, MD.
Journal: Blood
Blood (2004) 104 (11): 4291.
https://doi.org/10.1182/blood.V104.11.4291.4291
Published: 2004
Journal Articles

Pre-Transplantation FDG-PET Is the Best Predictor for Outcome in Relapsed Lymphoma Patients Treated with Autologous Stem Cell Transplantation.

Bart Schot, MD, Wim Sluiter, PhD, Gustaaf van Imhoff, MD, Jan Pruim, PhD, Miryam de Brouwer, Carolien Verhoogt, Wim Vaalburg, PhD, Edo Vellenga, PhD.
Journal: Blood
Blood (2004) 104 (11): 3260.
https://doi.org/10.1182/blood.V104.11.3260.3260
Published: 2004
Journal Articles

Increased Peripheral Platelet Destruction and Caspase-3-Independent Programmed Cell Death of Bone Marrow Megakaryocytes in Myelodysplastic Patients.

Ewout J. Houwerzijl, MD, Nel R. Blom, MD, Johannes J.L. van der Want, MD, Henk Louwes, PhD, Mariet T. Esselink, MD, Jan W. Smit, PhD, Edo Vellenga, PhD, Joost Th.M. de Wolf, PhD
Journal: Blood
Blood (2004) 104 (11): 2373.
https://doi.org/10.1182/blood.V104.11.2373.2373
Published: 2004